This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Diagnosis

Authoring team

Diagnosis of parvovirus B19 infection is done by measuring (1)

  • specific IgM and IgG antibodies to parvovirus B19
  • IgM is useful in diagnosing acute infection in immuncompetent patients
  • sensitivity is 89% and specificity is 99% (2)
  • IgM is seen 10–12 days after infection and usually persists for another 3-4 months (occasionally for a longer period) (1)
  • presence of IgG without IgM indicates previous infection of more than two months (3)
  • in the absence of both IgG and IgM, a second serum test should be done one month after the contact date or after symptoms appear
    • if IgM is detected a further test should be done within 7 to 10 days and if felt appropriate refer the patient to a reference laboratory for confirmation of the test (3)
  • B19 DNA in blood or tissue samples through PCR (1)
    • B19 DNA can be detected in serum, bone marrow and other tissues for diagnostic purposes (1)
    • important in diagnosing parvovirus infection in patients with transient aplastic crisis or in immunocompromised patients with chronic infection (2)
  • infection with erythrovirus (parvovirus) B19 may result in a false positive Paul Bunnell test

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.